Potential $400bn AstraZeneca‑BMS Merger Talks
AstraZeneca PLC (NYSE:AZN) and Bristol‑Myers Squibb Company (NYSE:BMY) have been holding confidential discussions over the past several months about a possible combination that would create a pharmaceutical group valued at approximately $400 billion, according to a Financial Times report citing people familiar with the matter. The report notes that the talks could be delayed or collapse, and no deal structure has been disclosed; neither company has issued a comment.
AstraZeneca’s current market capitalisation is about $264 billion, while Bristol‑Myers Squibb’s is roughly $133 billion. On the most recent trading day, AstraZeneca’s shares closed at $169.64, down $1.70 and more than $40 below the 52‑week high of $212.71. Bristol‑Myers Squibb’s shares closed at $65.31, just $0.35 shy of its 52‑week high of $65.66, on an above‑average volume of 14.58 million shares.
Both companies reported strong second‑quarter 2026 results. AstraZeneca posted earnings per share (EPS) of $2.63 versus the consensus estimate of $2.48, on revenue of $15.38 billion, slightly below the consensus of $15.45 billion. Bristol‑Myers Squibb reported EPS of $2.04, beating the consensus of $1.61, on revenue of $12.97 billion, exceeding the consensus estimate of $11.71 billion. BMS’s share price has risen about 47.7 % over the past year, helped by a robust Q2 and by oncology and immunology assets, including partnerships with BioNTech and Hengrui Pharma.
Strategically, AstraZeneca, under CEO Pascal Soriot, previously rebuffed a $118 billion takeover bid from Pfizer in 2014 and has recently announced a $50 billion U.S. manufacturing and R&D investment and plans for a direct U.S. listing. Bristol‑Myers Squibb has been pursuing acquisitions to offset patent‑cliff pressures; its GAAP R&D spend fell roughly 11 % to about $10 billion in 2025.
Regulatory approval would be complex. A cross‑border merger of this magnitude would attract simultaneous review by the U.S. Federal Trade Commission, the United Kingdom Competition and Markets Authority, and the European Commission.
The next scheduled earnings releases will provide the first formal market update. Bristol‑Myers Squibb is set to report Q3 2026 results on 29 October, with consensus expectations of $1.61 EPS on $12.04 billion revenue. AstraZeneca will report on 30 October, with consensus EPS of $2.63 on $16.06 billion revenue. Any announcement before these dates could reshape guidance conversations.